4th Covalent Drug Discovery & Development Summit (October 20–22, Boston, MA)

Covalent drug discovery is entering a defining era. Once constrained by safety and selectivity concerns, advances in chemistry, screening technologies, and translational science are unlocking covalent approaches as a powerful strategy to target previously inaccessible biology.

As the field evolves, the challenge is no longer proving potential. The priority is successful clinical translation. From predicting off-target toxicity to optimizing PK/PD and dose selection, teams continue to face uncertainty when moving from discovery into the clinic. Many programs still encounter critical gaps in translating promising preclinical data into patient outcomes.

The 4th Covalent Drug Discovery & Development Summit is the only industry-led forum dedicated to bridging discovery through to clinical application. Designed to unite medicinal chemists, chemical biologists, translational scientists, and early clinical leaders, the meeting delivers a truly end-to-end perspective across covalent drug development, now with expanded clinical content reflecting the growing pipeline of first-in-human and Phase II programs.

Across two conference days and interactive workshops, attendees will gain practical, actionable insights to:

• Design safer, more selective covalent compounds using novel warheads and structure-guided approaches
• De-risk development through advanced toxicity, reactivity, and safety assessment strategies
• Integrate translational data to improve in vitro to in vivo correlation and support confident clinical decisions
• Expand the druggable space by targeting new residues and previously undruggable biology

With case studies spanning AI-driven discovery, chemoproteomics, kinetic assays, and translational workflows, the summit showcases how the field is moving beyond traditional targets and into next-generation covalent therapies.

Bringing together 80+ senior leaders from pharma, biotech, and academia, this is a highly curated environment for deep technical exchange, collaboration, and real-world problem solving.

Whether you are optimizing discovery, scaling translational strategy, or preparing for the clinic, this is the critical forum to understand what it truly takes to move covalent therapies from concept to clinic and to help shape the next wave of precision medicines.